A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids

Journal of Rheumatology

Volumn 30, Issue 1, 2003, Pages 132-138

  Buckley, Lenore M ^a   Hillner, Bruce E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Bisphosphonates; Calcium; Corticosteroids; Glucocorticoids; Osteoporosis; Vitamin D

Indexed keywords

ALENDRONIC ACID; CALCIUM; ETIDRONIC ACID; GLUCOCORTICOID; PREDNISONE; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CASE REPORT; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIET SUPPLEMENTATION; DISEASE SEVERITY; FEMALE; HUMAN; LUMBAR SPINE; OSTEOPENIA; OSTEOPOROSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; THEORETICAL MODEL; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

ADULT; AGED; ALENDRONATE; BONE DENSITY; CALCIUM; COST-BENEFIT ANALYSIS; ESTROGEN REPLACEMENT THERAPY; ETIDRONIC ACID; FEMALE; GLUCOCORTICOIDS; HUMANS; MIDDLE AGED; OSTEOPOROSIS; RISK FACTORS; SPINAL FRACTURES; VITAMIN D;

EID: 0037224895     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.
2. Saag K, Koehnke R, Caldwell J, et al. Low dose long-term corticosteroid therapy in RA: an analysis of serious adverse events. Aro Am J Med 1994;96:115-23.
3. Laan R, Buijs W, van Erning L, et al. Differential effects of glucocorticoid on cortical appendicular and cortical vertebral bone mineral content. Calcif Tissue Int 1993;2:5-9.
4. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995;54:49-52.
5. Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 1995;54:810-6.
6. Beat AM, Bloch DA, Wolfe F, Fries JF. Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheumatol 1993;20:1666-9.
7. Hooyman JR, Melton LJ III, Nelson AM, Ofallon WM, Riggs BL. Fractures after rheumatoid arthritis. Arthritis Rheum 1984;27:1353-61.
8. Van Staa TP,Leufkens HGM, Abenhaim BZ, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Min Res 2000;15:993-1000.
9. Saag K, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
10. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent glucocorticoid-induced osteoporosis. N Engl J Med 1997;382-7.
11. Buckley LM, Leib ES, Cartularo KM, Vacek PM, Cooper SM. Calcium and vitamin D supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 1996;125:961-8.
12. Adachi JD, Bensen WG, Bianchi F, et al. Vitamin D and calcium in the prevention of glucocorticoid induced osteoporosis: a 3 year follow up. J Rheumatol 1996;23:995-1000.
13. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993;328:1747-52.
14. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994;33:348-50.
15. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-18.
16. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Min Res 1992;7:1063-9.
17. Hall GM, Daniels M, Doyl DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994;37:1499-505.
18. Healey JH, Paget SA, Williams-Russo P, et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 1996;58:73-80.
19. Kotaniemi A, Piirainen H, Paimela L, et al. Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy? J Rheumatol 1996;23:1875-9.
20. Ringe JD, Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 1987;33:35-9.
21. Montemurro L, Schiraldi G, Fraioli P, Tosi G, Riboldi A, Rizzato G. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991;49:71-6.
22. American College of Rheumatology task-force on osteoporosis guidelines: Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39:1791-801.
23. Reid I. Preventing glucocorticoid-induced osteoporosis. N Engl J Med 1997;337:420-1.
24. Sambrook PN, Jones G. Corticosteroid osteoporosis. Br J Rheumatol 1995;34:8-12.
25. Eastell R, Reid DM, Compston J, et al. A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J Intem Med 1998;244:271-92.
26. Kanis J. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994;4:368-81.
27. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000;12:1-12.
28. Hawley DA, Adachi JD, Annastassiade TP, et al. Prevention of corticosteroid osteoporosis with etidronate: one year follow up with calcium only. Bone 1998;23:S310.
29. Brown JP, Olszynski WP, Hodsman A, et al. Positive effects of etidronate is maintained after drug is terminated in patients using corticosteroids. J Clin Densitom 2001;4:363-71.
30. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919-23.
31. Liberman UA, Weiss SR, Broll J, et al. for the Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in post-menopausal osteoporosis. N Engl J Med 1995;333:1437-43.
32. Naganathan V, Nash P, Jones G, Nicholson G, Sambrook P. Vertebral fracture risk with long-term corticosteroids: Relationship to age and bone density. J Bone Miner Res 1999;14 Suppl 1:S139.
33. Melton LJ III, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL. Epidemiology of vertebral fractures in women. Am J Epidemiol 1989;129:1000-11.
34. Ross PD. Clinical consequences of vertebral fracture. Am J Med 1997;103 Suppl 2A:30S-43S.
35. Chrichilles E, Shireman T, Wallace R. Costs and health effects of osteoporotic fractures. Bone 1994;15:377-86.
36. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
37. US Bureau of the Census. Current Population Report P60-2000. Money income in the United States: 1997 (with separate data on valuation of noncash benefits). US Government Printing Office, Washington; 1998.
38. De Roos AJ, Callahan LF. Differences by sex in correlates of work status in rheumatoid arthritis patients. Arthritis Care Res 1999;12:381-91.
39. Nevitt M, Palermo L, Thompson D, et al. Back pain and related disability before and after clinically diagnosed vertebral fractures. J Bone Min Res 2000;15:S187.
40. Nevitt MC, Ettinger B, Black M, et al. The association of radiographically detected vertebral fractures with back pain and function: A prospective study. Ann Intern Med 1998;128:793-800.
41. Ensrud KE, Thompson DE, Cauley JA. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. J Am Geriatr Soc 2000;48:338-9.
42. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001-5.
43. Ismail AA, ONeill TW, Cooper C, et al. Mortality associated with vertebral deformity in men and women: Results from the European Prospective Osteoporosis Study (EPOS). Osteoporosis Int 1998;8:291-7.
44. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997;103 Suppl 2A:12S-10S.
45. Spector TD, McCloskey EV, Doyle DV, Kanis JA. Prevalence of vertebral fracture in women and the relationship with bone density and symptoms: The Chingford Study. J Bone Miner Res 1993;8:817-22.
46. Cook DJ, Guyatt GH, Adachi JD, et al. Quality of life issues in women with vertebral fractures due to osteoporosis. Arthritis Rheum 1993;36:750-6.
47. Gabriel SE, Kneeland TS, Melton LJ, Moncur MM, Ettinger B, Tosteson ANA. Health-related quality of life in economic evaluations for osteoporosis. Med Decis Making 1999;19:141-4.
48. Tosteson AN. Quality of life in the economic evaluation of osteoporosis prevention and treatment. Spine 1997;22 Suppl 24:58S-62S.
49. Dere W, Avouac B, Boers M, et al. Recommendations for the health economics analysis to be performed with a drug to be registered in prevention or treatment of osteoporosis. Calcif Tissue Int 1998;63:93-7.
50. Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2000;85:727-33.
51. Nashel DJ. Is atherosclerosis a complication of long-term corticosteroid treatment. Am J Med 1986;80:925-9.
52. Black DM, Sarkar S, Mitlak B, Knickerbocker R, Cummings SR. What proportion of the effects ofraloxifene (RLX) on vertebral fracture risk can be directly attributed to its bone mineral density (BMD) effects? J Bone Miner Res 1999;14 Suppl 1:S158.
53. Black DM, Pearson J, Harris F, LaCroix A, Cummings SR. Predicting the effect of antiresorptive treatment on risk of vertebral fractures: A meta-analysis. J Bone Miner Res 1999;14 Suppl 1:S137.
54. Ensrud KE, Nevitt MC, Palermo L, Cauley JA, Griffith JM, Genant HK, Black DM. What proportion of incident morphometric vertebral fractures are clinically diagnosed and vice versa? J Bone Miner Res 1999;14 Suppl 1:S138.
55. Buckley LM, Marquez M, Hudson JO, et al. Variations in physicians' judgments about corticosteroid-induced osteoporosis by physician specialty. J Rheumatol 1998;25:2195-202.
56. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996;313:344-6.
57. Buckley LM, Marquez M, Freezor R, Ruffin DM, Benson LL. Prevention of corticosteroid-induced osteoporosis. Arthritis Rheum 1999;42:1736-9.
58. Aagaard EM, Lin P, Modin GW, Lane NE. Prevention of glucocorticoid-induced osteoporosis: provider practice at an urban county hospital. Am J Med 1999;107:456-60.
59. Mudano A, Allison J, Hill J, Rothermel T, Saag K. Variations in glucocorticoid osteoporosis in a managed care cohort. J Rheumatol 2001;28:1298-305.